2-[4-(1,3,4-Oxadiazol-2-yl)phenyl]acetonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-(1,3,4-Oxadiazol-2-yl)phenyl]acetonitrile
• 化学式: C₁₀H₇N₃O
• mdl: MFCD01934464
• 分子量: 185.18
• InChiKey: BEIYRTTYQPHPTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  62.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  sodium methylate 、 2-[4-(1,3,4-Oxadiazol-2-yl)phenyl]acetonitrile 、 1-azido-2-fluoro-4-(trifluoromethyl)benzene 在 ice 、 氮气 、 水 、 乙酸乙酯 、 magnesium sulfate 、 crude residue 、 silica gel 、 petroleum ether 作用下， 以 甲醇 为溶剂， 反应 17.0h， 以to afford a pink solid (0.74 g, 97% mass balance)的产率得到3-(2-Fluoro-4-trifluoromethyl-phenyl)-5-(4-[1,3,4]oxadiazol-2-yl-phenyl)-3H-[1,2,3]triazol-4-ylamine
  参考文献：
  名称：

  1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors

  摘要：

  本发明涉及新型的1,2,3-三唑衍生物，发现它们是乙酰胆碱受体调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统有关的疾病或障碍，与平滑肌收缩有关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，与炎症、疼痛和终止滥用化学物质引起的戒断症状有关的疾病或障碍具有用处。

  公开号：

  US08110588B2

文献信息

• [EN] NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] DÉRIVÉS INÉDITS DE 1,2,3-TRIAZOLE UTILISABLES EN TANT QUE MODULATEURS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
  申请人：NEUROSEARCH AS

  公开号：WO2009019278A1

  公开（公告）日：2009-02-12

  This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及新型的1,2,3-三唑衍生物，发现它们是尼古丁型乙酰胆碱受体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病、神经退行性疾病、炎症、疼痛以及由滥用化学物质终止引起的戒断症状等疾病或障碍具有用处。
• NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：Nardi Antonio

  公开号：US20100222398A1

  公开（公告）日：2010-09-02

  This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新颖的1,2,3-三唑衍生物，这些衍生物被发现是乙酰胆碱受体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或障碍、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛和化学物质滥用终止引起的戒断症状等疾病或障碍有用。
• US8110588B2
  申请人：——

  公开号：US8110588B2

  公开（公告）日：2012-02-07
• 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
  申请人：Neurosearch A/S

  公开号：US08110588B2

  公开（公告）日：2012-02-07

  This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型的1,2,3-三唑衍生物，发现它们是乙酰胆碱受体调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统有关的疾病或障碍，与平滑肌收缩有关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，与炎症、疼痛和终止滥用化学物质引起的戒断症状有关的疾病或障碍具有用处。